{"name":"Viridian Therapeutics","slug":"viridian","ticker":"VRDN","exchange":"NASDAQ","domain":"viridiantherapeutics.com","description":"Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Walt","hq":"Waltham, MA","founded":0,"employees":"252","ceo":"Jonathan Violin, PhD","sector":"Endocrinology / Ophthalmology","stockPrice":17.68,"stockChange":0.64,"stockChangePercent":3.76,"marketCap":"$1.8B","metrics":{"revenue":70918000,"revenueGrowth":95.8,"grossMargin":0,"rdSpend":34794000,"netIncome":-342601000,"cash":762180992,"dividendYield":0,"peRatio":-6.6,"fiscalYear":"FY2015"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Veligrotug (VRDN-001)","genericName":"Veligrotug (VRDN-001)","slug":"veligrotug-vrdn-001","indication":"Hypercholesterolemia and dyslipidemia in patients with cardiovascular disease or at high cardiovascular risk","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"VRDN-003","genericName":"VRDN-003","slug":"vrdn-003","indication":"Graves' disease (hyperthyroidism)","status":"phase_3"}]}],"pipeline":[{"name":"Veligrotug (VRDN-001)","genericName":"Veligrotug (VRDN-001)","slug":"veligrotug-vrdn-001","phase":"phase_3","mechanism":"Veligrotug is a selective thyroid hormone receptor beta (THR-β) agonist that activates thyroid hormone signaling to reduce cholesterol and triglycerides.","indications":["Hypercholesterolemia and dyslipidemia in patients with cardiovascular disease or at high cardiovascular risk"],"catalyst":""},{"name":"VRDN-003","genericName":"VRDN-003","slug":"vrdn-003","phase":"phase_3","mechanism":"VRDN-003 is a monoclonal antibody that targets and inhibits thyroid-stimulating immunoglobulin (TSI) to reduce autoimmune thyroid activation in Graves' disease.","indications":["Graves' disease (hyperthyroidism)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Viridian Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Viridian Therapeutics reported its fourth quarter and full year 2023 financial results, with a net loss of $24.4 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Viridian Therapeutics Announces $50 Million Private Placement Financing","summary":"Viridian Therapeutics announced a $50 million private placement financing to support the development of its pipeline candidates.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxNaGNCZXUxWERHZXhLYVMxOFBMa2MzcE10dXRCeUpfMTZwcEJOYzZ5ZWdtVGRwcVpRU1Y1cUNnY0tFWmFVZXY2VldwQjctSWVnUjF2N08wN21YZVdCNFFNamRRVGFydEFUT0dKN3BCWlE2RnBaSHphZ0RTaFNpWHlWYmZpblM3WmxkZFVNNlF5R0dPMTk5SFkwZE94ZVNjTHp4alhXQ0dvaDZrU21NTTZYOFp3amdzMV9wYWhLamNHMHBGQ2p4bmNWdUFESWNTcVlMZURuVTNOS3FLQm4wQ2xlbEFwU3pjRWEydWpKSERjUGFYX1gwY1RONmFIaGJ0eDZ2ZVItVnRzRXhDZDdOU1JDM1JaRjNJX1ZJcms0LUtwOWo?oc=5","date":"2026-04-07","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Viridian Therapeutics (VRDN) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Viridian Therapeutics (VRDN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgJBVV95cUxOMUcwSDU2R0VWd0Q3MWRoY25QM3ByWkctQThhWVZWTzE1cm1weEJkd25OZlVKdWc1eXhqZkItdHZuRExFbEI0TklTcnhsR0RZZHJUQVlrellfR3B4b3FyZ3NCSTl0SVU0dDY5QzVyc3JnX2VQc0JfTElESkliWGNDQjMtSzlMZ21ibUNkaks0aUtZa1REQmFqbmJZRy1OMThmTzZSZkx1Um1Kdm5oNTdTcXJjdFYzMFVHcVg4UnlWVE0yZlBCWW5QR1g4NExsSzFtWnk4UjAzckdxT0IyamhRbnpHTXdKR1R2UHViSTR6UGx4bjlHZGMtWGNDOTd0SDdKbnVQeldZTDRFUnp5Ump0MUJxcDhDNktDcXc?oc=5","date":"2026-04-07","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Soleno Therapeutics (SLNO) and Viridian Therapeutics (VRDN) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Soleno Therapeutics (SLNO) and Viridian Therapeutics (VRDN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxOLVp3UE1SUjVFeEg2YVR5X2NvS2JHY2lCdFdmUmdkU2hOTXQ4eGZjaW9LOERPbEM5eC1SSkY2OVFHYUlxYUh2Q21kWGZ4SXpFY2p2M0puQzBXaFFUcG5Vbk10SmlRSXUwN1I2aWtuZTJrdUVYS1NYeWRqX1lGd2JIOHF0VWlmMVdKYVNpRjBKelpQbGVfcWJjSHUteWVFWnduYzFqeGo1amFzSmJzTFdfaUJQUXVZNmdtc2xkSnlaVDIzVDVPR2tjek1Zcw?oc=5","date":"2026-03-30","type":"trial","source":"Reuters","summary":"Viridian sinks as eye disease drug disappoints on efficacy despite trial success - Reuters","headline":"Viridian sinks as eye disease drug disappoints on efficacy despite trial success","sentiment":"negative"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNT2dySHEybks5UEIxQjU1ak1lY0dLZm5JRmlONWM1NzByc2RiSURvX3dnaGZuYVRpLTBfMzNFOTN0YnpkeXZXZzVGd2xoUU4xQWdoTExMOFJiVDJhMThtWElURXRoT29QUVFxampXb2RzeG5nTnliTk9PeVBJSXc4QnFtWTRuWTVrUTZ3T3l5T01UYmN4YUVSeFVjR0xDZENlTDRoRVNpUHVFZGc?oc=5","date":"2026-01-26","type":"pipeline","source":"Seeking Alpha","summary":"Viridian Therapeutics: Cautious Optimism As Key Milestones Approach (Rating Downgrade) - Seeking Alpha","headline":"Viridian Therapeutics: Cautious Optimism As Key Milestones Approach (Rating Downgrade)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOTHpRbmxlUGMwdENPMklJZl9zX2hMN1V5UXM1SW4zS3RqSDJkZEJpUGhLanprSnRUN1VvV0NNcktBUFpqcGFnZ0M0RzZoNUw4eEEtYnRxamhrc3ZpTGg1eDZiWVNSQWlzV0VvRkluY2lOT01aMDVlR2pGRGN1N2hDdTZNSDFhSDRjUHZMcF8xcTBWRkxTb2hkc1dKNll2OVc3YTQ3ZHQtcWpHZnNvaDVXRndOVQ?oc=5","date":"2026-01-06","type":"pipeline","source":"Business Wire","summary":"Viridian Therapeutics Prepares for Transformational 2026 - Business Wire","headline":"Viridian Therapeutics Prepares for Transformational 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPM0FvdW05RkxUOE1ZdE1BM1BnMkR0VWdqTFNSR3NfZzk1MDNfQ091YjJoV2J0V1lSaGhVeU9PWThlY0l3dzFwWG8tSVNUUFlBVV95ZHRNRUlxSFV6YTZzOXdBTlcxN1IxN2ZmYUo2T2tDSmg0d0VUZ2VXRDg0RVYyRVBNQ3RNdWNJWENWaGlUcXFxQUkzb25QOURmbmN3Vnhx?oc=5","date":"2025-10-21","type":"pipeline","source":"The Pharma Letter","summary":"Viridian announces up to $300 million royalty financing - The Pharma Letter","headline":"Viridian announces up to $300 million royalty financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxObkpSQ005WUFFMG5lMTlBS2FvOTVYNVdvMlhJSUlGV0ZPSTUweUtYT25TMkpSRVR4VjlmMTVndkRlTEhJZE03MmF1RlpmUDVYRW9kTUc1MnlXejY1TFlBLU5DZnBaWWxWSFFWUFhsT0hzRGFDUE9WRG0zc0FHYXdOT2E4VXVlOGZmVTRCVkRQcFZNc0c2dHBYN1IxbWZxZHl2dnlncWJHTVliYXkySmdwRXEwNjFhTy1jOVZ2clVtWTZ5Z1V2TzVPenNEWW5Wd0hTd1FVQ3c4Zi1LaXBwMkprN2lHWm9ZOTljRVVmbQ?oc=5","date":"2025-10-21","type":"pipeline","source":"Business Wire","summary":"Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock - Business Wire","headline":"Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQczh1WnlPYjBjdXdzb25SMnRoT1Y5LXNGVGhDbURnMVAxZFNfNXVlMGVTRTBJOWRQNnhFX0pBUE1BVXh6YzBoT3RFTGlIbmVPTW4zMWJwYTlrQ1pfWlBOd3J4cEJnNDNFemhJalBOUktkY1JaVFVFbzk0bXJlVm9meUFIa2xJN3VDTmNWeG5FQzB0b192bjBkY194Z1VBQnhSM2Q0d2pkOHJYSl85dk1Qb1Bja1FxMEl4c3ktdzkyYy02dw?oc=5","date":"2025-08-04","type":"deal","source":"Optometry Times","summary":"Viridian partners with Kissei Pharmaceutical to advance thyroid eye disease therapies in Japan - Optometry Times","headline":"Viridian partners with Kissei Pharmaceutical to advance thyroid eye disease therapies in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxPdi1mS042N05aV0Z5YklTeF92Y2pGMzFkdnBNbWtuNEZEUHZna2hpeTNIUy1JT3lwQ1BZZXhvSDBqYzJYTF9DSXRxQzdtYlEwLVBPYVF1V0tJcGtxbXZROEhwLTVDTV8yLW9LUWlRbnA0Y3c1Sjl1cHFlVVBJS25nV1owRnJQdnhnRl9jUW9aajRiNF9ScEdpbEkwVFFlTjNzRlpaU2QzaVZpSzgyNVdjeDZ0MWswUThETWg1MzVNSUQzOU5Nby1uOXB6RFBuOUlsVkVqVW9GaExydGl3Xzhra0VKazc?oc=5","date":"2025-07-31","type":"deal","source":"Pharmaceutical Executive","summary":"Viridian Therapeutics and Kissei Pharmaceutical Enter $70 Million Collaboration and License Agreement to Develop Veligrotug & VRDN-003 - Pharmaceutical Executive","headline":"Viridian Therapeutics and Kissei Pharmaceutical Enter $70 Million Collaboration and License Agreement to Develop Veligro","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPREpoOVRNLWNOQlVsd3FGQU9jbHFSREJ1aVVqVXNOV2gyWUNfYnhxeUoxdWFqX3ZQTVhwODZkdVpoNVBSVm0xdDB2UGpLZG5ZZVRLLWEzNGg5c2I1Yy1xSXZRbGhTTVJDV2kxU1pKUUEyOEdmT3RoelRLVF9YSnR0SGYyTFZMcjE3SGdz?oc=5","date":"2025-07-31","type":"pipeline","source":"Pharmaceutical Technology","summary":"Viridian and Kissei to advance veligrotug and VRDN-003 in Japan - Pharmaceutical Technology","headline":"Viridian and Kissei to advance veligrotug and VRDN-003 in Japan","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-30","type":"deal","source":"BioSpace","summary":"Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and ","headline":"Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQbXNQbUR5OGVBRHV3UnhZNWlLdGliVThyWlJ2TmQ1dzNUVjIxNFQ2ZGpHRzV3cVU0ZjF4aC1OZjQ5MWxmV0JJUkwyVC1LSGFWY09VMnItWkMyVXFFc0dxWERkcXBGc08wUml0Rk0zTXE2VnhHWWNSbkxxYXVZSmNVWGxWTWJtX2o1YkJuR0d1X2FkcWZRaGVoSU14MHpyRXdRVGp6U0dnaVFTZw?oc=5","date":"2025-07-30","type":"pipeline","source":"Fierce Biotech","summary":"Kissei pays Viridian $70M to challenge Amgen for Japanese eye disease market - Fierce Biotech","headline":"Kissei pays Viridian $70M to challenge Amgen for Japanese eye disease market","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Regeneron Pharmaceuticals","Sanofi","Novartis"],"therapeuticFocus":["Endocrinology","Ophthalmology"],"financials":{"source":"sec_edgar+yahoo","revenue":5706000,"revenuePeriod":"2015-12-31","revenueHistory":[{"value":5706000,"period":"2015-12-31"},{"value":6484000,"period":"2014-12-31"},{"value":6484000,"period":"2014-12-31"},{"value":5491000,"period":"2013-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":34794000,"rdSpendHistory":[{"period":"2025-12-31","value":338929000},{"period":"2024-12-31","value":238254000},{"period":"2023-12-31","value":159765000},{"period":"2022-12-31","value":100894000}],"sgaSpend":95315000,"operatingIncome":-363395000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-363395000},{"period":"2024-12-31","value":-299035000},{"period":"2023-12-31","value":-254450000},{"period":"2022-12-31","value":-134304000}],"netIncome":-342601000,"netIncomeHistory":[{"period":"2025-12-31","value":-342601000},{"period":"2024-12-31","value":-269949000},{"period":"2023-12-31","value":-237734000},{"period":"2022-12-31","value":-129874000}],"eps":-3.32,"epsHistory":[{"period":"2025-12-31","value":-3.32},{"period":"2024-12-31","value":-3.07},{"period":"2023-12-31","value":-5.31},{"period":"2022-12-31","value":-4.05}],"cash":212382000,"cashHistory":[{"period":"2025-12-31","value":212382000},{"period":"2024-12-31","value":99594000},{"period":"2023-12-31","value":102827000},{"period":"2022-12-31","value":155579000}],"totalAssets":899418000,"totalLiabilities":177251000,"totalDebt":50693000,"equity":722167000,"operatingCashflow":-276391000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-276391000},{"period":"2024-12-31","value":-232319000},{"period":"2023-12-31","value":-184170000},{"period":"2022-12-31","value":-93838000}],"capex":-495000,"capexHistory":[{"period":"2025-12-31","value":-495000},{"period":"2024-12-31","value":-511000},{"period":"2023-12-31","value":-898000},{"period":"2022-12-31","value":-797000}],"freeCashflow":-276886000,"dividendsPaid":null,"buybacks":null,"employees":252,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":33673000,"ebit":-117073000,"ebitda":-116953000,"period":"2025-12-31","revenue":132000,"epsBasic":-1.08,"netIncome":-120355000,"rdExpense":89208000,"epsDiluted":-1.08,"grossProfit":null,"operatingIncome":-122749000},{"sga":24322000,"ebit":-34039000,"ebitda":-33929000,"period":"2025-09-30","revenue":70570000,"epsBasic":-0.34,"netIncome":-34599000,"rdExpense":86261000,"epsDiluted":-0.34,"grossProfit":null,"operatingIncome":-40013000},{"sga":20216000,"ebit":-100221000,"ebitda":-100108000,"period":"2025-06-30","revenue":75000,"epsBasic":-1,"netIncome":-100735000,"rdExpense":86626000,"epsDiluted":-1,"grossProfit":null,"operatingIncome":-106767000},{"sga":17103000,"ebit":-86326000,"ebitda":-86209000,"period":"2025-03-31","revenue":72000,"epsBasic":-0.87,"netIncome":-86912000,"rdExpense":76835000,"epsDiluted":-0.87,"grossProfit":null,"operatingIncome":-93866000},{"sga":15584000,"ebit":-78867000,"ebitda":-78744000,"period":"2024-12-31","revenue":72000,"epsBasic":-0.81,"netIncome":-79725000,"rdExpense":71960000,"epsDiluted":-0.81,"grossProfit":null,"operatingIncome":-87472000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":17.68,"previousClose":17.04,"fiftyTwoWeekHigh":34.29,"fiftyTwoWeekLow":12.13,"fiftyTwoWeekRange":"12.133 - 34.29","fiftyDayAverage":20.15,"twoHundredDayAverage":24.32,"beta":0.82,"enterpriseValue":1179618560,"forwardPE":-6.6,"priceToBook":3.05,"priceToSales":25.7,"enterpriseToRevenue":16.63,"enterpriseToEbitda":-3.06,"pegRatio":0,"ebitda":-385233984,"ebitdaMargin":0,"freeCashflow":-182550752,"operatingCashflow":-303392000,"totalDebt":53350000,"debtToEquity":8.4,"currentRatio":15.15,"returnOnAssets":-33.2,"returnOnEquity":-58.1,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":16,"targetMeanPrice":34.56,"targetHighPrice":50,"targetLowPrice":20,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.1,"institutionHeldPercent":104.5,"sharesOutstanding":103074740,"floatShares":97599410,"sharesShort":11512229,"shortRatio":3.37,"shortPercentOfFloat":11.2,"epsTrailing":-3.35,"epsForward":-2.67,"revenuePerShare":0.79,"bookValue":5.79,"officers":[{"age":54,"name":"Mr. Stephen F. Mahoney J.D., MBA","title":"CEO, President & Director"},{"age":44,"name":"Mr. Seth  Harmon","title":"Chief Financial Officer"},{"age":55,"name":"Mr. Thomas W. Beetham J.D., MBA","title":"Chief Operating Officer"},{"age":52,"name":"Ms. Jennifer  Tousignant J.D.","title":"Chief Legal Officer & Corporate Secretary"},{"age":45,"name":"Dr. Radhika  Tripuraneni M.D., M.P.H.","title":"Chief Medical Officer"},{"age":null,"name":"Dr. Eric N. Olson Ph.D.","title":"Co-Founder & Chairman of Scientific Advisory Board"},{"age":80,"name":"Dr. Michael R. Bristow M.D., Ph.D.","title":"Co-Founder & Member of the Scientific Advisory Board"},{"age":85,"name":"Dr. Marvin H. Caruthers Ph.D.","title":"Co-Founder & Scientific Advisory Board Member"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.viridiantherapeutics.com","phone":"617 272 4600"}}